유방조직의 c-kit와 COX-2의 발현과 의의
Significance of c-kit and COX-2 Expression in Breast Tissue
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background : The proto-oncogene c-kit encodes a transmembrane tyrosine kinase growth factor receptor. Studies have shown that c-kit is highly expressed in normal breast epithelium, but expression is decreased in primary breast cancer. Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid to prostaglandins. Expression of COX-2 has been reported in malignant tumors including breast cancer. We evaluated the expression of c-kit and COX-2 in benign and malignant lesions of the breast to assess the roles of these proteins in cancer initiation and progression. Methods : We characterized 20 benign lesions, 20 intraductal carcinomas and 70 invasive breast carcinomas. Immunohistochemical staining for c-kit and COX-2 was performed. Results : Expression of c-kit was detected in 75% of the benign breast lesions, 40% of the intraductal carcinomas and 10% of the invasive carcinomas. COX-2 expression was observed in 80% of the benign lesions, 70% of the intraductal carcinomas and 52% of the invasive carcinomas. Expression of c-kit was significantly correlated with tumor size (p=0.02). COX-2 expression was significantly correlated with negative expression of estrogen receptor and progesterone receptor (p=0.02, p=0.04), Her-2/neu expression (p=0.008) and the high proliferation index (p=0.0002). Conclusions : Our results suggest that c-kit and COX-2 might be involved in malignant transformation of the mammary epithelium and tumor progression. It is suggested that c-kit and COX-2 can be used as predictive markers and therapeutic targets.
참고문헌 (29)
- 한국중앙암등록사업 연례 보고서(2002.1-2002.12), "보건복지부 한국중앙암등록본부", ~ (2003)
- Vliagoftis H, "The protooncogene c-kit and c-kit ligand in human disease", J Allergy Clin Immunol, 100, pp.435~440 (1997)
- Heinrich MC, "Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations", Hum Pathol, 33, pp.484~495 (2002)
- Seidal T, "Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours", Histopathology, 34, pp.416~424 (1999)
- Tian Q, "Activating c-kit gene mutations in human germ cell tumors", Am J Pathol, 154, pp.1643~1647 (1999)
- Plummer H 3rd, "c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines", Cancer Res, 53, pp.4337~4342 (1993)
- Lassam N, "Loss of c-kit expression in cultured melanoma cells", Oncogene, 7, pp.51~56 (1992)
- Natali PG, "Breast cancer is associated with loss of the c-kit oncogene product", Int J Cancer, 52, pp.713~717 (1992)
- Chui X, "Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues", Br J Cancer, 73, pp.1233~1236 (1996)
- Roussidis AE, "The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer", Curr Med Chem, 14, pp.735~743 (2007)
- Eberhart CE, "Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas", Gastroenterology, 107, pp.1183~1188 (1994)
- Soslow RA, "COX-2 is expressed in human pulmonary, colonic, and mammary tumors", Cancer, 89, pp.2637~2645 (2000)
- Schreinemachers DM, "Aspirin use and lung, colon, and breast cancer incidence in a prospective study", Epidemiology, 5, pp.138~146 (1994)
- Ristimaki A, "Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer", Cancer Res, 62, pp.632~635 (2002)
- Half E, "Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ", Cancer Res, 62, pp.1676~1681 (2002)
- Arun B, "The role of COX-2 inhibition in breast cancer treatment and prevention", Semin Oncol, 31, pp.22~29 (2004)
- Orejuela FJ, "Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium", Gynecol Oncol, 97, pp.483~488 (2005)
- Mauro MJ, "STI571: targeting BCR-ABL as therapy for CML", Oncologist, 6, pp.230~232 (2001)
- Joensuu H, "Management of malignant gastrointestinal stromal tumours", Lancet Oncol, 3, pp.655~664 (2002)
- Tsuura Y, "Preferential localization of ckit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma", dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffinembedded tissues, 1994, pp.424, 135~141
- Yared MA, "Expression of c-kit proto-oncogene product in breast tissue", Breast J, 10, pp.323~327 (2004)
- Diallo R, "C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2", neu, 2006, pp.37, 205~211
- Eroglu A, "Expression of c-kit proto-oncogene product in breast cancer tissues", Med Oncol, 24, pp.169~174 (2004)
- Howe LR, "Cyclooxygenase- 2: a target for the prevention and treatment of breast cancer", Endocr Relat Cancer, 8, pp.97~114 (2001)
- Van Rees BP, "Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract", Scand J Gastroenterol, 36, pp.897~903 (2001)
- Liu CH, "Overexpression of cyclooxygenase- 2 is sufficient to induce tumorigenesis in transgenic mice", J Biol Chem, 267, pp.18563~18569 (2001)
- Shim V, "Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium", Cancer Res, 63, pp.2347~2350 (2003)
- Boland GP, "COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ", Br J Cancer, 90, pp.423~429 (2004)
- Ranger GS, "Elevated cyclooxygenase -2 expression correlates with distant metastases in breast cancer", Anticancer Res, 24, pp.2349~2351 (2004)